Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Watch

Enzymes That Catalyze Wobble tRNA Modification Promote Melanomagenesis

DOI: 10.1158/2159-8290.CD-RW2018-109 Published August 2018
  • Article
  • Info & Metrics
  • PDF
Loading
  • Major finding: Enzymes that modify wobble uridine 34 tRNAs (U34 enzymes) maintain HIF1α levels in BRAFV600E melanoma.

  • Concept: U34 enzymes promote glycolysis through direct, codon-dependent regulation of HIF1A translation.

  • Impact: U34 enzyme upregulation in patients with BRAFV600E may be a mechanism of resistance to RAF inhibitors.


Embedded Image

Aberrant mRNA translation can promote tumorigenesis and drug resistance, but the molecular mechanisms have not been fully elucidated. Wobble tRNA modifications are essential for the translation of specific codons, and the enzymes that carry out the modifications of wobble uridine 34 tRNA (U34 enzymes) were shown to be upregulated in BRAFV600E melanoma cells in zebrafish. Rapino and colleagues found that the U34 enzymes ELP1, ELP3, and CTU2 were also upregulated in human melanomas and melanoma cell lines, indicating a potential role for U34 tRNA modification in BRAFV600E melanomagenesis. The HIF1A mRNA sequence is enriched for codons that require U34 tRNA modifications, suggesting that it requires U34 enzymes for accurate translation. Indeed, the U34 enzymes promoted codon-dependent regulation of HIF1A translation, thereby increasing HIF1α levels to promote glycolytic gene expression in BRAFV600E melanoma cells and reducing the dependence on the tricarboxylic acid cycle. Further, HIF1α loss phenocopied U34 enzyme loss of function and reduced the survival of BRAFV600E cells. Patients with BRAFV600E melanoma often respond to RAF inhibitors, but rapidly develop acquired resistance. Analysis of data from The Cancer Genome Atlas revealed that U34 enzymes were upregulated in patients who had acquired resistance to the RAF inhibitor vemurafenib, and increased expression of U34 enzymes was also linked to increased HIF1α levels, suggesting that U34 enzymes may be associated with resistance to RAF inhibitors in patients with BRAFV600E melanoma. Moreover, U34 enzyme depletion resensitized vemurafenib-resistant BRAFV600E cells to RAF inhibition. In vivo, inhibition of ELP3 or CTU2 sensitized resistant melanoma xenografts to vemurafenib. Activation of PI3K signaling, which is one mechanism of resistance to RAF inhibition, increased U34 enzyme levels, elucidating a potential role for U34 enzymes in drug resistance. In addition to demonstrating that U34 enzymes maintain HIF1α levels, these findings suggest a role for U34 enzymes in melanoma progression and drug resistance.

Rapino F, Delaunay S, Rambow F, Zhou Z, Tharun L, De Tullio P, et al. Codon-specific translation reprogramming promotes resistance to targeted therapy. Nature 2018;558:605–9.

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

  • ©2018 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 8 (8)
August 2018
Volume 8, Issue 8
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Enzymes That Catalyze Wobble tRNA Modification Promote Melanomagenesis
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Enzymes That Catalyze Wobble tRNA Modification Promote Melanomagenesis
Cancer Discov August 1 2018 (8) (8) 910; DOI: 10.1158/2159-8290.CD-RW2018-109

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Enzymes That Catalyze Wobble tRNA Modification Promote Melanomagenesis
Cancer Discov August 1 2018 (8) (8) 910; DOI: 10.1158/2159-8290.CD-RW2018-109
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • FBXO44 Silences Repetitive Elements during DNA Replication in Cancer
  • Epstein–Barr Virus–Induced Antitumor Immune Response May Be Harnessable
  • Cryo-EM Structures Reveal Mechanism of Anticancer MCT1 Inhibitors
Show more Research Watch

Translation

  • KRAS-Driven Cancers Are Dependent on METTL13-Mediated eEF1A Methylation
  • METTL3 Promotes mRNA Translation to Drive Tumorigenesis
Show more Translation
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement